Inhibitors of serine proteases, particularly hepatitis C virus NS3-NS4 protease

Details for Australian Patent Application No. 2003223602 (hide)

Owner Vertex Pharmaceuticals Incorporated

Inventors Pitlik, Janos; PerniI, Robert B; Van Drie, John H; Farmer, Luc J; Cottrell, Kevin M; Murcko, Mark A; Courtney, Lawrence F

Agent Cullens

Pub. Number AU-B-2003223602

PCT Number PCT/US03/11459

PCT Pub. Number WO2003/087092

Priority 60/371,846 11.04.02 US

Filing date 11 April 2003

Wipo publication date 27 October 2003

Acceptance publication date 13 May 2010

International Classifications

C12N 9/99 (2006.01) Enzymes, e.g. ligases (6.) - Enzyme inactivation by chemical treatment

A61K 38/00 (2006.01) Medicinal preparations containing peptides

A61K 38/04 (2006.01) Medicinal preparations containing peptides - Peptides having up to 20 amino acids in a fully defined sequence

A61P 1/16 (2006.01) Drugs for disorders of the alimentary tract or the digestive system

A61P 31/12 (2006.01) Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

A61P 31/14 (2006.01) Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

A61P 37/02 (2006.01) Drugs for immunological or allergic disorders

A61P 43/00 (2006.01) Drugs for specific purposes, not provided for in groups

C07D 209/42 (2006.01) Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom

C07D 401/12 (2006.01) Heterocyclic compounds containing two or more hetero rings

C07D 403/12 (2006.01) Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group

C07D 405/12 (2006.01) Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom

C07D 405/14 (2006.01) Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom

C07D 417/12 (2006.01) Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group

C07D 471/04 (2006.01) Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups

C07K 5/04 (2006.01) Peptides having up to four amino acids in a fully defined sequence

C07K 5/06 (2006.01) Peptides having up to four amino acids in a fully defined sequence

C07K 5/10 (2006.01) Peptides having up to four amino acids in a fully defined sequence

C07K 7/02 (2006.01) Peptides having 5 to 20 amino acids in a fully defined sequence

Event Publications

7 August 2003 Complete Application Filed

  Priority application(s): 60/371,846 11.04.02 US

4 December 2003 Application Open to Public Inspection

  Published as AU-B-2003223602

13 May 2010 Application Accepted

  Published as AU-B-2003223602

27 May 2010 Corrigenda

  Applications Accepted - Name Index Under the name Vertex Pharmaceuticals Incorporated, Application No. 2003223602, under INID (72) correct the coinventor to read Perni, Robert B.

9 September 2010 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2003223603-LAMBDA SENSING WITH A FUEL CELL STACK

2003223601-ANTI-INFLAMMATORY AND WOUND HEALING EFFECTS OF LYMPHOID THYMOSIN Beta 4